MarginsXMarginsX
Home › Markets › Health Care › LITS

Lite Strategy Inc. (LITS)

LITS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$0.8565
+1.16% on the day
Market cap
$25.6M
Nano cap
Revenue · 2026
$267K
Prior year not contiguous
Net income · 2026
-$71.2M
-26647.9% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:InterestAndDividendIncomeOperating), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1262104/000119312526405328/0001193125-26-405328-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2026-06-30.

Profile

FieldValue
TickerLITS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2003
SEC CIK0001262104
SEC industry codeFinance Services
Incorporated inDE

Financials · 2026

LineValue
Revenue$267K
Net income-$71.2M
Operating income-$66.6M
Net margin-26647.9%
Operating margin-24935.2%
Revenue growthNo prior-year revenue to compare
Cash$5.7M
Total assets$42.7M
P/E (computed)Net income was not positive
P/S (computed)95.9×

Warning signs

Cash runway
7.6 months
$4.3M cash at September 30, 2026
Share count, 1 year
-18.8%
2025-11-08 to 2026-10-30 · +348.5% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
-$804K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$4.3M cash; operating cash flow -$1.7M a quarter.Report 2026-09-30
Shares outstanding29,884,653 (2026-10-30); 36,785,397 a year earlier; 6,662,857 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-09-28
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorCBIZ CPAs P.C., Costa Mesa, California, United States; changed auditors 1 time in 24 months8-K 4.01 2025-12-05
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $142K, sold $946K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
Not filed$16.0M-$2.2M$4.3MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2026
2026-06-30
$53K-$13.0M-$1.2M$5.7MNo debt tags$267K10-K 2026-09-28
Q3 2026
2026-03-31
$54K-$23.7M-$1.5M$7.5MNo debt tagsNeeds four quarters10-Q 2026-05-13
Q2 2026
2025-12-31
$60K-$30.8M-$1.9M$8.8MNo debt tagsNeeds four quarters10-Q 2026-02-17
Q1 2026
2025-09-30
Not filed-$3.6M-$4.5M$10.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-06-30
$0-$2.7M-$2.5M$18.0MNo debt tags$010-K 2025-09-26
Q3 2025
2025-03-31
$0-$2.6M-$3.3M$20.5MNo debt tags$010-Q 2025-05-13
Q2 2025
2024-12-31
$0-$2.7M-$3.7M$23.7MNo debt tags$010-Q 2025-02-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-32026-09-28
Latest annual report10-K2026-09-28
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-03
Latest proxyDEFA14A2026-01-27

Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-16.7%
1 month-29.8%
3 months-5.6%
Year to date-35.6%
1 year-55.3%
From 52-week high-57.9%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
EDSAEdesa Biotech Inc. Common Shares$1.89-2.58%$25.5M
ACETAdicet Bio Inc.$2.75-1.08%$25.7M
ABVCABVC BioPharma Inc.$0.9400+3.30%$25.4M
CRVOCervoMed Inc.$1.67-1.18%$25.3M
IMMPImmutep Limited$3.40-2.30%$25.1M
MIRAMIRA Pharmaceuticals Inc.$0.6310-4.38%$26.5M
RMTIRockwell Medical Inc.$6.76-4.38%$26.9M
IXHLIncannex Healthcare Inc.$1.93-2.03%$24.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier